Compound ID | 1799
Class: Natural product antibiotic
| Agent Type: | Natural product; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | DNA synthesis inhibitor. Bacterial topoisomerase inhibitor |
| Target Pathogen: | Active against Enterobacteriaceae and Acinetobacter |
| Description: | Natural compound; non-ribosomally synthesized peptide antibiotics produced by different myxobacteria; evaluated as a potential alternative to fluoroquinolones |
| Institute where first reported: | Myxobiotics (Helmholtz Institute for Pharmaceutical Research Saarland), Evotec |
| Year first mentioned: | 2019 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/90646593 |
| Citations: |
|